The stock of Eli Lilly and Company (NYSE:LLY) increased by $9.72 on Monday to finish at $538.00, up 1.84 percent. The last five days have seen an average of 6,216,980 shares of common stock traded. 28 times new highs were reached in the current year, with a gain of $172.16. The average number of shares traded over the last 20 days was 3,127,220, while the average volume over the last 50 days totaled 2,852,404.
LLY stock appreciated 19.70% since last month. On 07/17/23, the company’s shares reached a one-month low of $443.26. The stock touched a high of $538.00 on 08/14/23, after rallying from a low of $296.32 in 52 weeks. The price of LLY stock has risen by 47.06% or $172.16 this year, reaching a new high 28 times. Still, the stock price is down 0.00% from the 52-week high.
Insider Transactions
LLY stock investors should be aware that Eli Lilly and Company (LLY) stock had its last reported insider trading activity 4 days ago on Aug 11. On Aug 11, 10% Owner ELI LILLY & Co acquired 1,718,493 shares at $14.92 each. This transaction resulted in the insider spending $25,639,916. On Aug 11, LILLY ENDOWMENT INC sold 83,039 shares at a price of US$528.50. After the transaction, the insider now owns 100,613,810 shares. 10% Owner LILLY ENDOWMENT INC had earlier sold 3,000 shares on Aug 10 for $528.13 a share. The transaction was completed for $1,584,405.
Valuation Metrics
Eli Lilly and Company (LLY) has a trailing price-to-earnings (P/E) ratio of 74.74. Beta for the stock is 0.32. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 17.08, the price-to-book (PB) ratio of 43.73, and the price-to-cash flow ratio of 156.94.
Company paid $1.13 per share in dividends, remained unchanged from $1.13 last year.
Financial Health
For the three months ended June 29, Eli Lilly and Company’s quick ratio was 0.90, while its current ratio was 1.10, indicating its inability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 1.64, and the total debt to equity ratio is 1.70. As far as profitability goes, gross margin for the trailing twelve months is 77.80% percent. Based on annual data, it had gross profit of $21.91 billion and revenue of $28.54 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. There was a 24.40% return on investment (ROI) in the past year.
Earnings Surprise
According to Eli Lilly and Company’s quarterly financial report for the quarter that ended June 29, it had $18.16 billion in total debt versus $134.6 million in cash and short-term investments. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $8.31 billion, while revenues rose by 21.95% to $6.96 billion. It was predicted that Eli Lilly and Company’s quarterly earnings would be $2.11, but it ended up being $1.98, beating the consensus by 6.60%. EBITDA was $2.49 billion for the quarter. At the end of Eli Lilly and Company’s most recent quarter ended June 29, its liabilities totaled 43.66 billion, while its total debt was $18.95 billion. Equity owned by shareholders amounts to $949.29 million.
Technical Picture
Here’s a quick look at Eli Lilly and Company’s (LLY) price momentum from a technical perspective. As of 14 August, the RSI 9-day stood at 84.84%, suggesting the stock is Overbought, with a 66.92% historical volatility rate.
The stochastic %K and %D were 88.89% and 86.21% respectively, while the average true range (ATR) was 14.73. Based on the 14-day stochastic reading of 95.51%, the RSI (14) reading is 79.89%. On the 9-day MACD Oscillator, the stock is at 35.58, and the 14-day reading is at 49.40.
Analyst Ratings
In its most recent analyst report, Jefferies raised its rating on Eli Lilly and Company (NYSE: LLY) to a Buy. Prior to this, analysts firm rated the stock as a Hold. Analysts have assigned Eli Lilly and Company (LLY) an Overweight rating. LLY is a stock that is recommended for selling by 1 brokerage firm, while 6 companies recommend holding. The stock is underweighted by 1 analyst. Among the analysts who rate the stock, 1 rate it overweight and 20 others recommend it as a buy.
What is LLY’s price target for the next 12 months?
The current consensus forecast for the stock is between $300.00 and $633.00, with a median target price of $585.00. In analyzing these forecasts, the average price target given by analysts for Eli Lilly and Company (LLY) is $543.49.
